Difference between revisions of "Sorafenib (Nexavar)"
m |
m |
||
| Line 19: | Line 19: | ||
==History of changes in FDA indication== | ==History of changes in FDA indication== | ||
| − | *12/20/2005: [http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/2005/ucm108538.htm FDA approved] "for the treatment of patients with advanced renal cell carcinoma (RCC)." | + | *12/20/2005: [http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/2005/ucm108538.htm FDA approved] "for the treatment of patients with advanced [[Renal cancer | renal cell carcinoma (RCC)]]." |
| − | *11/16/2007: [http://www.fda.gov/AboutFDA/CentersOffices/OfficeofMedicalProductsandTobacco/CDER/ucm129234.htm FDA approved] "for the treatment of patients with unresectable hepatocellular carcinoma (HCC)." | + | *11/16/2007: [http://www.fda.gov/AboutFDA/CentersOffices/OfficeofMedicalProductsandTobacco/CDER/ucm129234.htm FDA approved] "for the treatment of patients with unresectable [[Hepatobiliary cancer | hepatocellular carcinoma (HCC)]]." |
| − | *11/22/2013: [http://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm376547.htm FDA approved] "for the treatment of locally recurrent or metastatic, progressive, differentiated thyroid carcinoma (DTC) refractory to radioactive iodine treatment" | + | *11/22/2013: [http://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm376547.htm FDA approved] "for the treatment of locally recurrent or metastatic, progressive, [[Thyroid cancer | differentiated thyroid carcinoma (DTC)]] refractory to radioactive [[Iodine | iodine]] treatment" |
==Also known as== | ==Also known as== | ||
| Line 42: | Line 42: | ||
[[Category:Renal cancer medications]] | [[Category:Renal cancer medications]] | ||
[[Category:Thyroid cancer medications]] | [[Category:Thyroid cancer medications]] | ||
| + | |||
| + | [[Category:Drugs FDA approved in 2005]] | ||
Revision as of 15:06, 25 October 2014
General information
Class/mechanism: Tyrosine kinase inhibitor that inhibits multiple kinases: CRAF, BRAF, KIT, FLT-3, RET, vascular endothelial growth factor receptors VEGFR-1, VEGFR-2, VEGFR-3, and platelet-derived growth factor receptor beta (PDGFR-B). Inhibition of these kinases disrupts angiogenesis, tumor cell signaling, and induces apoptosis.[1][2][3]
Route: PO
Extravasation: n/a
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.[1]
Diseases for which it is used
Patient drug information
- Sorafenib (Nexavar) package insert PDF pages 26-30[1]
- Sorafenib (Nexavar) patient drug information (Chemocare)[4]
- Sorafenib (Nexavar) patient drug information (UpToDate)[5]
History of changes in FDA indication
- 12/20/2005: FDA approved "for the treatment of patients with advanced renal cell carcinoma (RCC)."
- 11/16/2007: FDA approved "for the treatment of patients with unresectable hepatocellular carcinoma (HCC)."
- 11/22/2013: FDA approved "for the treatment of locally recurrent or metastatic, progressive, differentiated thyroid carcinoma (DTC) refractory to radioactive iodine treatment"
Also known as
Sorafenib Tosilate